Euro vs US Dollar

Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.

Registrieren

ADAG

Adagene (ADAG)

Adagene Inc

Von:

Regulatory News

Text Search:

Sortieren nach:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:ADAG

1 2 3 Next >>

Datum	Zeit	Quelle	Überschrift	Symbol	Firma
29/03/2024	14h00	GlobeNewswire Inc.	Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update	NASDAQ:ADAG	Adagene Inc
07/03/2024	22h01	GlobeNewswire Inc.	Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board	NASDAQ:ADAG	Adagene Inc
01/03/2024	22h30	Edgar (US Regulatory)	Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]	NASDAQ:ADAG	Adagene Inc
27/02/2024	14h00	GlobeNewswire Inc.	Adagene to Present at the Leerink Partners Global Biopharma Conference 2024	NASDAQ:ADAG	Adagene Inc
09/02/2024	12h08	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ADAG	Adagene Inc
09/02/2024	12h00	GlobeNewswire Inc.	Adagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with KEYTRUDA® (pembrolizumab) to Demonstrate Further Efficacy in Patients with Metastatic Microsatellite-stab	NASDAQ:ADAG	Adagene Inc
16/01/2024	23h01	GlobeNewswire Inc.	Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)	NASDAQ:ADAG	Adagene Inc
16/01/2024	23h00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ADAG	Adagene Inc
04/01/2024	11h00	GlobeNewswire Inc.	Adagene To Present Interim Results of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at ASCO-GI Symposium	NASDAQ:ADAG	Adagene Inc
03/11/2023	17h00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ADAG	Adagene Inc
03/11/2023	17h00	GlobeNewswire Inc.	Adagene Presents Data Demonstrating the Best-in-Class Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 at SITC 2023	NASDAQ:ADAG	Adagene Inc
12/10/2023	14h00	GlobeNewswire Inc.	Adagene Announces Poster Presentation on Optimal Dose Selection for Masked Anti-CTLA-4 SAFEbody® ADG126 at Upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting	NASDAQ:ADAG	Adagene Inc
29/09/2023	12h30	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ADAG	Adagene Inc
07/09/2023	12h00	GlobeNewswire Inc.	Adagene to Present at Investor and Scientific Conferences in September	NASDAQ:ADAG	Adagene Inc
31/08/2023	13h32	GlobeNewswire Inc.	Adagene Reports Six Month Financial Results for 2023 and Provides Corporate Update	NASDAQ:ADAG	Adagene Inc
31/08/2023	13h00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ADAG	Adagene Inc
07/07/2023	22h34	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ADAG	Adagene Inc
04/05/2023	15h01	Edgar (US Regulatory)	Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)	NASDAQ:ADAG	Adagene Inc
04/05/2023	15h00	GlobeNewswire Inc.	Adagene Achieves $3 Million Milestone in Collaboration with Exelixis for Successful Nomination of Second SAFEbody® Novel Masked Antibody-Drug Conjugate	NASDAQ:ADAG	Adagene Inc
28/04/2023	13h06	Edgar (US Regulatory)	Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)	NASDAQ:ADAG	Adagene Inc
28/04/2023	13h03	Edgar (US Regulatory)	Annual and Transition Report (foreign Private Issuer) (20-f)	NASDAQ:ADAG	Adagene Inc
28/04/2023	13h00	GlobeNewswire Inc.	Adagene Announces Updates to its Board of Directors	NASDAQ:ADAG	Adagene Inc
18/04/2023	15h27	Edgar (US Regulatory)	Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)	NASDAQ:ADAG	Adagene Inc
18/04/2023	15h17	GlobeNewswire Inc.	Adagene Presents Clinical Data for Anti-CTLA-4 SAFEbody® ADG126 Reinforcing Best-in-Class Safety Profile at Repeat Doses and Showing Early Efficacy Profile in Advanced/Metastatic Solid Tumors	NASDAQ:ADAG	Adagene Inc
28/03/2023	23h07	Edgar (US Regulatory)	Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)	NASDAQ:ADAG	Adagene Inc
28/03/2023	22h30	GlobeNewswire Inc.	Adagene Reports Full Year 2022 Financial Results and Provides Corporate Update	NASDAQ:ADAG	Adagene Inc
14/03/2023	23h00	GlobeNewswire Inc.	Adagene Announces Poster Presentations on Anti-CTLA-4 SAFEbody®, ADG126, at Upcoming American Association for Cancer Research (AACR) Annual Meeting in April	NASDAQ:ADAG	Adagene Inc
06/03/2023	01h39	GlobeNewswire Inc.	Adagene Appoints Professor Aurélien Marabelle to Scientific and Strategic Advisory Board	NASDAQ:ADAG	Adagene Inc
09/02/2023	14h16	Edgar (US Regulatory)	Amended Statement of Ownership (sc 13g/a)	NASDAQ:ADAG	Adagene Inc
06/02/2023	12h05	Edgar (US Regulatory)	Amended Statement of Ownership (sc 13g/a)	NASDAQ:ADAG	Adagene Inc

Showing the most relevant articles for your search:NASDAQ:ADAG

1 2 3 Next >>

iShares MSCI Europe IMI ...

Open Exchange Token

SUZBX520 Ex:51,01

Danieli & C Officine Mec...

Permian Resources

Ermenegildo Zegna NV

Vontobel Financial Produ...

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen